<?xml version='1.0' encoding='utf-8'?>
<document id="24798753"><sentence text="LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study."><entity charOffset="54-60" id="DDI-PubMed.24798753.s1.e0" text="PA-824" /><entity charOffset="62-74" id="DDI-PubMed.24798753.s1.e1" text="moxifloxacin" /><entity charOffset="79-91" id="DDI-PubMed.24798753.s1.e2" text="pyrazinamide" /><pair ddi="false" e1="DDI-PubMed.24798753.s1.e0" e2="DDI-PubMed.24798753.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24798753.s1.e0" e2="DDI-PubMed.24798753.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24798753.s1.e0" e2="DDI-PubMed.24798753.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24798753.s1.e1" e2="DDI-PubMed.24798753.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24798753.s1.e1" e2="DDI-PubMed.24798753.s1.e2" /></sentence><sentence text="A simple, sensitive and rapid LC-MS/MS method has been developed and validated for simultaneous determination of PA-824, moxifloxacin, and pyrazinamide in rat plasma using metronidazole as internal standard"><entity charOffset="113-119" id="DDI-PubMed.24798753.s2.e0" text="PA-824" /><entity charOffset="121-133" id="DDI-PubMed.24798753.s2.e1" text="moxifloxacin" /><entity charOffset="139-151" id="DDI-PubMed.24798753.s2.e2" text="pyrazinamide" /><entity charOffset="172-185" id="DDI-PubMed.24798753.s2.e3" text="metronidazole" /><pair ddi="false" e1="DDI-PubMed.24798753.s2.e0" e2="DDI-PubMed.24798753.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24798753.s2.e0" e2="DDI-PubMed.24798753.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24798753.s2.e0" e2="DDI-PubMed.24798753.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24798753.s2.e0" e2="DDI-PubMed.24798753.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24798753.s2.e1" e2="DDI-PubMed.24798753.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24798753.s2.e1" e2="DDI-PubMed.24798753.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24798753.s2.e1" e2="DDI-PubMed.24798753.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24798753.s2.e2" e2="DDI-PubMed.24798753.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24798753.s2.e2" e2="DDI-PubMed.24798753.s2.e3" /></sentence><sentence text=" Sample preparation involved a simple one-step protein precipitation with methanol, followed by centrifugation and evaporation of the organic solvent"><entity charOffset="74-82" id="DDI-PubMed.24798753.s3.e0" text="methanol" /></sentence><sentence text=" The residue was redissolved in mobile phase and analyzed by LC-MS/MS" /><sentence text=" An Inertsil(®) ODS3 C18 column (150mm×4" /><sentence text="6mm, 5μm), a mobile phase composed of methanol-0" /><sentence text="03% TEA (triethylamine) in water (85:15, v/v), and a flow rate of 0"><entity charOffset="4-7" id="DDI-PubMed.24798753.s7.e0" text="TEA" /><entity charOffset="9-22" id="DDI-PubMed.24798753.s7.e1" text="triethylamine" /><pair ddi="false" e1="DDI-PubMed.24798753.s7.e0" e2="DDI-PubMed.24798753.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24798753.s7.e0" e2="DDI-PubMed.24798753.s7.e1" /></sentence><sentence text="5mL/min were employed, and the total run time was 6" /><sentence text="0min" /><sentence text=" The mass spectrometer was run in positive ion ESI-APCI combined mode using multiple reaction monitoring (MRM) to monitor the mass transitions" /><sentence text=" The method was validated for accuracy, precision, linearity, range, selectivity, lower limit of quantification (LLOQ), recovery, and matrix effect" /><sentence text=" All validation parameters met the acceptance criteria according to regulatory guidelines" /><sentence text=" The LLOQ was 1" /><sentence text="0μg/mL for pyrazinamide and 0"><entity charOffset="11-23" id="DDI-PubMed.24798753.s14.e0" text="pyrazinamide" /></sentence><sentence text="1μg/mL for PA-824 and moxifloxacin"><entity charOffset="11-17" id="DDI-PubMed.24798753.s15.e0" text="PA-824" /><entity charOffset="22-34" id="DDI-PubMed.24798753.s15.e1" text="moxifloxacin" /><pair ddi="false" e1="DDI-PubMed.24798753.s15.e0" e2="DDI-PubMed.24798753.s15.e0" /><pair ddi="false" e1="DDI-PubMed.24798753.s15.e0" e2="DDI-PubMed.24798753.s15.e1" /></sentence><sentence text=" The recoveries obtained for PA-824, moxifloxacin and pyrazinamide were ≥85%"><entity charOffset="29-35" id="DDI-PubMed.24798753.s16.e0" text="PA-824" /><entity charOffset="37-49" id="DDI-PubMed.24798753.s16.e1" text="moxifloxacin" /><entity charOffset="54-66" id="DDI-PubMed.24798753.s16.e2" text="pyrazinamide" /><pair ddi="false" e1="DDI-PubMed.24798753.s16.e0" e2="DDI-PubMed.24798753.s16.e0" /><pair ddi="false" e1="DDI-PubMed.24798753.s16.e0" e2="DDI-PubMed.24798753.s16.e1" /><pair ddi="false" e1="DDI-PubMed.24798753.s16.e0" e2="DDI-PubMed.24798753.s16.e2" /><pair ddi="false" e1="DDI-PubMed.24798753.s16.e1" e2="DDI-PubMed.24798753.s16.e1" /><pair ddi="false" e1="DDI-PubMed.24798753.s16.e1" e2="DDI-PubMed.24798753.s16.e2" /></sentence><sentence text=" Intra-day and inter-day coefficients of variation were less than 10%" /><sentence text=" The method had been successfully applied to a pharmacokinetic study of fixed dose administration of PA-824, moxifloxacin, pyrazinamide and their combination in SD rat"><entity charOffset="101-107" id="DDI-PubMed.24798753.s18.e0" text="PA-824" /><entity charOffset="109-121" id="DDI-PubMed.24798753.s18.e1" text="moxifloxacin" /><entity charOffset="123-135" id="DDI-PubMed.24798753.s18.e2" text="pyrazinamide" /><pair ddi="false" e1="DDI-PubMed.24798753.s18.e0" e2="DDI-PubMed.24798753.s18.e0" /><pair ddi="false" e1="DDI-PubMed.24798753.s18.e0" e2="DDI-PubMed.24798753.s18.e1" /><pair ddi="false" e1="DDI-PubMed.24798753.s18.e0" e2="DDI-PubMed.24798753.s18.e2" /><pair ddi="false" e1="DDI-PubMed.24798753.s18.e1" e2="DDI-PubMed.24798753.s18.e1" /><pair ddi="false" e1="DDI-PubMed.24798753.s18.e1" e2="DDI-PubMed.24798753.s18.e2" /></sentence><sentence text=" Significant differences of Tmax, Cmax, AUC(0-t) and CLz/F were observed between the single and combined groups after equal dose of PA-824 and moxifloxacin administration, which revealed the possibility of drug-drug interaction (DDI) between the PaMZ combination"><entity charOffset="132-138" id="DDI-PubMed.24798753.s19.e0" text="PA-824" /><entity charOffset="143-155" id="DDI-PubMed.24798753.s19.e1" text="moxifloxacin" /><pair ddi="false" e1="DDI-PubMed.24798753.s19.e0" e2="DDI-PubMed.24798753.s19.e0" /><pair ddi="false" e1="DDI-PubMed.24798753.s19.e0" e2="DDI-PubMed.24798753.s19.e1" /></sentence><sentence text=" " /></document>